Thursday, August 30, 2018

Creative Proteomics Releases Peptide Mass Fingerprinting Service for Rapid Protein Identification as well as Further Scientific Research Assistance

New York - Aug 30th, 2018 - Creative Proteomics, the world’s leading proteome-related products and services provider, announces the launch of professional proteomics identification service include Peptide Mass Fingerprinting, De Novo Proteins Sequencing, and N-terminal Sequencing etc. which can help researchers get systematic bioinformatics analysis with comprehensive protein identification pipeline. The services released offered to involve the entire workflow which starts with sample preparation, protein separation and purification, followed by mass analysis.

Peptide Mass Fingerprinting, as the most common mass spectrometry protein identification technique, involving the production of peptides from proteins with residue-specific enzymes, the determination of peptide mass by spectrometric techniques, and matching these qualities to the theoretical peptide library generated by the protein sequence database to establish a list of possible protein identifications. At present, Peptide Mass Fingerprinting performs an amino acid analysis program on a sample to generate a list of best-matching proteins and analyzes duplicate samples to produce a separate list so that to achieve the identification while comparing the best matching protein lists for the same database. There are two applications for this technology, one is in the case where the protein is blocked at the N-terminus and cannot be used for ‘sequence tagging’, the other is in the case of identifying proteins at large or small phylogenetic distances across the boundaries of the species. As it shares the similar sample throughput to the AA analysis, this combinatorial identification method is suitable for rapid protein identification.

The De novo protein/peptide sequencing service interprets the MS spectrum from a first principle to determine the amino acid sequence, which can easily provide enough data to show homology to other proteins in order to obtain internal amino acid sequence information. Although mass spectrometry has been widely applied to process database search and identification of proteins, however, it still is not suitable while the protein sequence does not exist in the database. Therefore, De novo sequencing is widely used to identify new peptides, unsequencing organisms and antibody drugs that cannot be detected by database retrieval methods.

N-terminal sequence analysis involves a series of chemical reactions that derivatize and remove one amino acid at a time from the N-terminus of the purified peptide or intact protein. Despite the recent decline in the need for N-terminal sequencing, some applications for protein identification and characterization are now more efficiently performed with mass spectrometry. However, N-terminal sequencing still is applied to validate the N-terminal boundary of the recombinant protein, identify the N-terminus of the protease-resistant domain, also being taken as the identification method for selecting proteins isolated from species that have not been sequenced in most genomes, as well as mapping the modification or cross-linking sites in the protein, which proves difficult to analyze by mass spectrometry.

About Creative Proteomics

Founded in 2005, Creative Proteomics provide customers with a full range of proteomics service to support proteome-related research. We are dedicated to offering protein separation, characterization, identification and quantification services with the most advanced proteomics platforms in the world and in-house experienced proteomics professionals. As a well-recognized industry leader with more than 10 years experiences, Creative Proteomics has millions of active customers worldwide. 

Media Contact
Company Name: Creative Proteomics
Contact Person: Melissa George
Email:Send Email
Phone: 1-631-619-7922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States
Website: https://www.creative-proteomics.com